Balchem Corporation (BCPC)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Balchem Corporation.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 167.60 $ — 64% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 3.3% failed
- More than 10% revenue growth is expected for the coming year 5.3% failed
- Share count grows by less than 3% a year 0.2% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 25.4% failed
- Gross margin at 40% or higher and without meaningful erosion 35.7% failed
- Goodwill from acquisitions does not grow faster than revenue 47.8% passed
- Net debt below twice EBITDA 0.5 x EBITDA passed
- Operating cash flow covers the profits of the last three years 190 m passed
- Return on capital at 15% or higher, or up versus two years ago 14.3% passed
- Insiders hold at least 10% or are net buyers 0.5% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 19.8% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 2
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5.68 | 5.65 – 5.70 | 1,108 | 10.4% | 3 |
| 12/31/2027 | 6.11 | 5.85 – 6.33 | 1,167 | 7.5% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.03 | 25.70 | 240 | 4.90 | 14.00 | 52 | 40 |
| 2025: Q1 | 1.13 | 27.10 | 251 | 4.50 | 14.80 | 37 | 31 |
| 2025: Q2 | 1.17 | 19.00 | 256 | 9.10 | 15.00 | 47 | 40 |
| 2025: Q3 | 1.23 | 19.40 | 268 | 11.50 | 15.10 | 66 | 51 |
| 2025: Q4 | 1.21 | 17.60 | 264 | 9.80 | 14.90 | 67 | 51 |
| 2026: Q1 | 1.25 | 10.50 | 271 | 8.10 | 14.90 | 40 | 34 |
| 2026: Q2 | 1.39 | 18.80 | 284 | 11.20 | 15.70 | 47 | 47 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 553 | 91 | 56 | 1.75 | 108 | 521 | 949 |
| 2017 | 595 | 97 | 90 | 2.79 | 111 | 617 | 964 |
| 2018 | 644 | 107 | 79 | 2.42 | 119 | 692 | 981 |
| 2019 | 644 | 103 | 80 | 2.45 | 124 | 744 | 1,156 |
| 2020 | 704 | 111 | 85 | 2.60 | 150 | 828 | 1,166 |
| 2021 | 799 | 128 | 96 | 2.94 | 161 | 877 | 1,199 |
| 2022 | 942 | 145 | 105 | 3.25 | 139 | 938 | 1,625 |
| 2023 | 922 | 159 | 109 | 3.35 | 184 | 1,054 | 1,597 |
| 2024 | 954 | 183 | 128 | 3.93 | 182 | 1,150 | 1,575 |
| 2025 | 1,037 | 218 | 155 | 4.75 | 217 | 1,257 | 1,708 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Balchem Corporation entwickelt, fertigt und vertreibt Spezialleistungszutaten und -produkte für die Märkte Ernährung, Lebensmittel, Pharma, Tiergesundheit, Medizinproduktsterilisation, Pflanzenernährung und Industrie weltweit. Sie ist in drei Segmenten tätig: Human Nutritio…
| Employees | 1,368 |
|---|---|
| Headquarters | Montvale, NJ |
| Address | 5 Paragon Drive, 07645 Montvale, United States |
| Phone | 845 326 5600 |
| Website | balchem.com |
| IPO Date | 3. Jun 1986 |
| ISIN | US0576652004 |
| Stock Split | 3:2 on 01/21/2010 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Theodore Lee Harris | CEO, President & Chairman | 1965 |
| Carl Martin Bengtsson | Executive VP, CFO, Treasurer and GM of Animal Nutrition & Health | 1977 |
| Hatsuki Miyata J.D. | Executive VP, Chief Legal Officer & Secretary | 1976 |
| M. Brent Tignor | Senior VP & Chief Human Resources Officer | 1978 |
| Frederic Boned | Senior VP, Head of Digital Transformation & AI and GM of Human Nutrition & Health | 1979 |
| Erin L. Gilson | VP & Chief Accounting Officer | – |
| Martin Luther Reid | Senior VP & Chief Supply Chain Officer | 1967 |
| Job L. van Gunsteren | Senior VP & GM of Specialty Products | 1977 |
| George Graham | Senior VP and Chief R&D Officer | 1970 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.